![Send email](https://curamus-cancer.fr/wp-content/themes/curamus/assets/icones/mail-2-little.svg")
Neuro-oncology
Coordinated by Pr.Marc Sanson
Brain cancers are the 1st cause of cancer death before the age of 35. Because of their rarity, their great heterogeneity and their frequent resistance to conventional treatments, they remain poorly known.
The main objectives of this programme are to :
- Better understand functional genomics and the role of the tumor microenvironment
- Improving diagnosis through innovative and/or non-invasive approaches
- To develop personalized therapies and improve the quality of life of patients.
Synthesis for the general public
SonoCloud First Project
The SonoCloud First project, led by Prof. Alexandre Carpentier, head of the neurosurgery department at Pitié-Salpêtrière and coordinator of the […]
Chordoid glioma: a subtype of brain tumour still poorly understood
Chordoid glioma: a subtype of brain tumour still poorly understood Chordoid gliomas are rare brain tumours, resulting from the excessive […]
A glioma to kill
“A glioma to kill “ Short film by Nathalie Magne, post-PhD of the Sanson-Huillard’s team who, on the occasion of […]
Functional consequences of HDI1 and CIC mutations on the cells of origin of oligodendrogliomas
Functional consequences of HDI1 and CIC mutations on the cells of origin of oligodendrogliomas Oligodendrogliomas are primary tumours of the […]
Brain Tumours: Developing Individualized Therapies
Brain Tumours: Developing Individualized Therapies
CLIP2 Galilée website
Launch of the new CLIP² Galilé website The CLIP² Galilée (INCa Labeled Early Stage Centre), first labeled by the National […]
Genetics and mechanisms involved in resistance to brain tumor treatments
Genetics and mechanisms involved in resistance to brain tumor treatments In an article to be published in the prestigious journal […]
Publications
Genomics and molecular mechanism of gliomagenesis
E.HUILLARD- A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas. Rosenberg et al. Nat Commun. 2018 Jun.
- A metabolic function of FGFR3-TACC3 gene fusions in cancer. Frattini et al. Nature 2018 Jan.
- The molecular landscape of glioma in patients with Neurofibromatosis 1. D‘Angelo et al. Nat Med. 2019 Jan.
Improving glioma diagnosis through non-invasive approaches
F.BIELLE- FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas. Picca et al. Neurology 2018 Jun.
- Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy. Branzoli et al. Neuro-oncology 2018 Jun.
Search for new targeted therapies in relevant preclinical models
A.IDBAIH- Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma. Idbaih et al. Clin Cancer Res. 2019 Jul.
- Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Van den Bent et al. Lancet Oncol 2018 Sep.
- Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. Houillier et al. J Clin Oncol. 2019 Apr.
